Ceribell Bolsters Board with Healthcare and Medtech Veterans
Event summary
- Ceribell adds Thomas West and Sharon O’Keefe to its board of directors.
- West previously led Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B).
- O’Keefe served as President of University of Chicago Medical Center, overseeing $2B in annual revenue.
- Ceribell’s point-of-care brain monitoring platform is now deployed in 680 U.S. hospitals.
The big picture
Ceribell’s board additions signal a strategic push to scale its hospital footprint, combining West’s medtech M&A experience with O’Keefe’s health system operational expertise. The moves come as demand for AI-powered diagnostic tools grows in acute-care settings, positioning Ceribell to capitalize on the shift toward decentralized neurological monitoring.
What we're watching
- Commercial Expansion
- How Ceribell will leverage West’s medtech scaling expertise to accelerate adoption beyond 680 hospitals.
- Health System Strategy
- Whether O’Keefe’s academic health system leadership can drive deeper integration into large hospital networks.
- Category Leadership
- The pace at which Ceribell solidifies its position as the dominant player in point-of-care brain monitoring.